MSFT, BABA, and MRK lead today's top analyst picks, with AI, e-commerce, and cancer drug strategies in sharp focus.

German drugmaker Merck Serono is one step closer to releasing the first pill to treat multiple sclerosis, the company said Friday. In a press statement, Merck said that patients taking cladribine ...

Merck, a leading science and technology company, today announced it will present 39 abstracts at the 38th Congress of the European Committee for Treat ...

DUBLIN – Merck KGaA is terminating its interest in ATX-MS-1467 just ahead of a read-out from a phase II trial in multiple sclerosis and is handing back global rights to its original developer Apitope ...

Merck KGaA said on Wednesday the U.S. Food and Drug Administration (FDA) had paused the initiation of new patients on its multiple sclerosis evobrutinib drug, knocking the German drugmaker's share ...

Merck KGaA is laying the groundwork for its closely watched multiple sclerosis (MS) drug candidate. With phase 3 data imminent, the German drugmaker has begun an awareness campaign to inform ...

Germany's Merck KGaA said its experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials, dealing a major blow to the company's growth ...

Shares in Germany’s Merck fell after it said the FDA had placed a partial clinical hold on the initiation of new patients in the Phase 3 study of evobrutinib, the drugmaker’s treatment for ...

Merck KGaA, with hold still clouding prospects, guides MS drug past durability test ahead of phase 3 data By Nick Paul Taylor Oct 11, 2023 9:49am ...

Merck's multiple sclerosis drug evobrutinib didn't meet a key goal in late-stage trials. The German pharmaceutical company's phase 3 clinical trials for the drug did not achieve their primary ...

FRANKFURT (Reuters) -Merck KGaA's experimental multiple sclerosis (MS) drug missed the primary goal in highly anticipated late-stage trials, dealing a major blow to the German company's growth ...

Germany's Merck KGaA said on Wednesday the U.S. Food and Drug Administration (FDA) had paused the initiation of new patients on its multiple sclerosis evobrutinib drug, sending its share price ...